We scan new podcasts and send you the top 5 insights daily.
Clinicians must avoid co-administering proton pump inhibitors with the novel CELMoD mezigdomide. When gastrointestinal acid suppression is indicated, treating teams should switch patients to H2 receptor blockers to prevent adverse drug interactions.
Due to fedratinib's significant GI side effect profile and the logistical difficulty of measuring thiamine levels, clinicians should proactively provide patients with thiamine supplements, anti-emetics, and anti-diarrheal therapies. Instructing patients to take the drug with food can also help mitigate GI toxicity.
Given that diarrhea from Capivasertib has a rapid onset within 12 days, clinicians should consider prophylactic loperamide. This proactive approach, especially for patients with pre-existing bowel issues, can help them tolerate the therapy from the start, rather than waiting for symptoms to appear.
To manage the acute GI toxicity of T-DXd, a preemptive three-drug antiemetic combination is recommended. Completely preventing nausea and vomiting is crucial not just for comfort, but for mitigating patient anxiety around chemotherapy and ensuring they can remain on this long-term treatment.
The HORIZON-GEA-01 trial for zanidatumab in gastric cancer mandated prophylactic loperamide (4mg BID) for all patients. This was necessary to manage the high rates of diarrhea (up to 80% of patients), a significant GI toxicity associated with the drug's mechanism of action.
New targeted therapies like Zanidatamab and Zolbetuximab show great promise but cause significant side effects like diarrhea and nausea. Their successful clinical adoption hinges on proactive management using detailed guidelines and prophylactic medications, as toxicity can be severe enough to force treatment discontinuation despite the drug's efficacy.
Clinicians are finding that forgoing the standard 800mg loading dose of zolbituximab and starting directly with the 600mg maintenance dose appears to mitigate acute gastrointestinal toxicity, particularly gastritis. This practical adjustment is being formally studied but is already used in practice to improve patient experience.
Zolbituximab causes significant nausea and vomiting as a direct result of binding its Claudin 18.2 target in the stomach. Its clinical success depends on aggressively managing this on-target effect with prophylactic multi-drug antiemetics and adjusted infusion rates, particularly during the initial treatment cycle.
Common, OTC acid-reducing drugs can drastically inhibit TKI absorption, sometimes by more than half. This frequently overlooked drug interaction can cause suboptimal responses and treatment failure in CML patients. The lack of patient questioning about OTC use presents a significant and avoidable clinical risk.
While both approved oral SERDs are well-tolerated, they have distinct gastrointestinal side effect profiles. Elacestrant is more associated with upper GI issues like nausea (mitigated by taking it with food), whereas imlunestrant is linked to lower GI toxicity like diarrhea. This helps in drug selection and proactive patient counseling.
For a patient on TDXD plus pertuzumab who develops severe, treatment-limiting diarrhea, a reasonable strategy is to discontinue pertuzumab and continue with TDXD monotherapy. This preserves the most active agent while mitigating toxicity, as the incremental benefit of pertuzumab is not yet reported.